It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CVS’s FA Score shows that 2 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CVS’s TA Score shows that 6 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).
CVS (@Managed Health Care) experienced а -0.72% price change this week, while MRK (@Pharmaceuticals: Major) price change was +2.77% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was +0.33%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -2.66%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.91%. For the same industry, the average monthly price growth was +5.75%, and the average quarterly price growth was +4.68%.
CVS is expected to report earnings on Jul 30, 2025.
MRK is expected to report earnings on Jul 29, 2025.
Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
@Pharmaceuticals: Major (+2.91% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
CVS | MRK | CVS / MRK | |
Capitalization | 100B | 332B | 30% |
EBITDA | 18.2B | 6.91B | 264% |
Gain YTD | 44.914 | -19.931 | -225% |
P/E Ratio | 12.33 | 935.64 | 1% |
Revenue | 358B | 60.1B | 596% |
Total Cash | 11.5B | 7.09B | 162% |
Total Debt | 79.4B | 35.1B | 226% |
CVS | MRK | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 81 | 74 | |
SMR RATING 1..100 | 78 | 25 | |
PRICE GROWTH RATING 1..100 | 54 | 64 | |
P/E GROWTH RATING 1..100 | 17 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CVS's Valuation (3) in the Drugstore Chains industry is in the same range as MRK (10) in the Pharmaceuticals Major industry. This means that CVS’s stock grew similarly to MRK’s over the last 12 months.
MRK's Profit vs Risk Rating (74) in the Pharmaceuticals Major industry is in the same range as CVS (81) in the Drugstore Chains industry. This means that MRK’s stock grew similarly to CVS’s over the last 12 months.
MRK's SMR Rating (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for CVS (78) in the Drugstore Chains industry. This means that MRK’s stock grew somewhat faster than CVS’s over the last 12 months.
CVS's Price Growth Rating (54) in the Drugstore Chains industry is in the same range as MRK (64) in the Pharmaceuticals Major industry. This means that CVS’s stock grew similarly to MRK’s over the last 12 months.
CVS's P/E Growth Rating (17) in the Drugstore Chains industry is significantly better than the same rating for MRK (100) in the Pharmaceuticals Major industry. This means that CVS’s stock grew significantly faster than MRK’s over the last 12 months.
CVS | MRK | |
---|---|---|
RSI ODDS (%) | 1 day ago66% | 1 day ago41% |
Stochastic ODDS (%) | 1 day ago62% | 1 day ago52% |
Momentum ODDS (%) | 1 day ago63% | 1 day ago48% |
MACD ODDS (%) | 1 day ago62% | 1 day ago45% |
TrendWeek ODDS (%) | 1 day ago58% | 1 day ago49% |
TrendMonth ODDS (%) | 1 day ago54% | 1 day ago46% |
Advances ODDS (%) | 8 days ago62% | 3 days ago47% |
Declines ODDS (%) | 2 days ago60% | 24 days ago49% |
BollingerBands ODDS (%) | 1 day ago67% | 1 day ago45% |
Aroon ODDS (%) | 1 day ago55% | N/A |
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.
Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
---|---|---|---|---|
MRK | 100% | +1.74% | ||
PFE - MRK | 46% Loosely correlated | +0.99% | ||
ABBV - MRK | 41% Loosely correlated | +1.26% | ||
AZN - MRK | 40% Loosely correlated | +0.73% | ||
AMGN - MRK | 40% Loosely correlated | +1.13% | ||
BIIB - MRK | 39% Loosely correlated | +2.12% | ||
More |